Skip to main content
MSLE
NASDAQ Life Sciences

Satellos to Present New Clinical Data for SAT-3247 at ICNMD 2026

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$5.62
Mkt Cap
$117.071M
52W Low
$5.44
52W High
$144
52W Position info
3.3% above low
Off High info
96% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

MSLE is trading near its 52-week low of $5.44 (3.3% above the low).

Summary

Satellos Bioscience announced it will present new six-month follow-up data from its Phase 1b SAT-3247 trial and updates on its Phase 2 TRAILHEAD study at the ICNMD 2026 conference in July.


Key Events · Product Development and Regulatory · MSLE

  • New Clinical Data Presentation Announced

    Satellos Bioscience will present new data from its SAT-3247 clinical development program at the 19th International Congress on Neuromuscular Diseases (ICNMD) from July 7–11, 2026.

  • Phase 1b Follow-Up and Phase 2 Updates

    The presentation will include six-month follow-up data from participants in the Phase 1b SAT-3247-CL-101 trial and updates from the ongoing Phase 2 TRAILHEAD (LT-001) trial for Duchenne muscular dystrophy.

  • Lead Candidate for Degenerative Muscle Diseases

    SAT-3247 is an investigational oral small molecule drug candidate being developed for Duchenne muscular dystrophy and other degenerative muscle diseases, currently in Phase 2 studies (TRAILHEAD and BASECAMP).


Analysis · MSLE · Life Sciences

This filing announces that Satellos Bioscience will present new clinical data for its lead drug candidate, SAT-3247, at a major international conference in July. The presentation will include six-month follow-up data from a Phase 1b trial and updates on the ongoing Phase 2 TRAILHEAD study for Duchenne muscular dystrophy. For a clinical-stage biotech, these updates are critical for investor confidence and future development, especially as the company is trading near its 52-week low.

How filings like this one have moved

In the 30 days to Nov 6, 2026, 35.1% of the 2636 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, MSLE was trading at $5.62 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $117.1M. The 52-week trading range was $5.44 to $144.00. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

MSLE - Latest Insights

MSLE
Nov 06, 2026, 7:00 AM EST
Filing Type: 6-K
Importance Score:
8
Price at Filing: $6.00
Real-time Price: $7.19 info
Change: +$1.19 (+20%) info
Market Cap: $152.546M info
MSLE
Sep 30, 2026, 7:00 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $8.60
Real-time Price: $7.19 info
Change: -$1.41 (-16%) info
Market Cap: $152.546M info
MSLE
Sep 24, 2026, 7:00 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $8.91
Real-time Price: $7.19 info
Change: -$1.72 (-19%) info
Market Cap: $152.546M info
MSLE
Aug 13, 2026, 5:03 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $9.82
Real-time Price: $7.19 info
Change: -$2.63 (-27%) info
Market Cap: $152.546M info
MSLE
Jul 08, 2026, 6:30 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $8.37
Real-time Price: $7.19 info
Change: -$1.18 (-14%) info
Market Cap: $152.546M info